[{"from": "human", "value": "Provide a description of this molecule. [C][C][=C][Branch2][Ring2][#C][C][Branch2][Ring1][N][C][=Branch1][Branch2][=C][Branch1][Ring2][N][Ring1][=Branch1][C][P][=Branch1][C][=O][O][C][C][Branch1][Branch1][C][O][Ring1][#Branch1][Branch1][C][C][C][C][=C][C][=Branch1][=Branch1][=C][C][=C][Ring1][=Branch1][N+1][=Branch1][C][=O][O-1][C][=Branch1][C][=O][O][C][C][N][Branch1][#Branch2][C][C][=C][C][=C][C][=C][Ring1][=Branch1][C][=C][C][=C][C][=C][Ring1][=Branch1]"}, {"from": "gpt", "value": "The molecule is a calcium channel blocker of the dihydropyridine class, commercialized by Shionogi & Co. (Japan). Initially, it was marketed in 1995 under the trade name, Landel. The drug has been shown to block T-type in addition to L-type calcium channels. It has also been studied in atherosclerosis and acute renal failure. This drug is also known as NZ-105, and several studies have been done on its pharmacokinetics in animals."}]